Nuveen LLC Takes $609,000 Position in Accuray Incorporated $ARAY

Key Points

• Nuveen LLC has acquired a new position in Accuray Incorporated, purchasing 340,303 shares valued at approximately $609,000, representing 0.33% ownership as of the latest SEC filing.
• Accuray's stock recently opened at $1.46, with a market cap of $164.51 million and a PE ratio of -73.00, while the stock has seen a one-year range between $1.14 and $2.95.
• Analysts have differing views on Accuray, with BTIG Research raising the price target to $5.00, while Wall Street Zen downgraded its rating from "hold" to "sell."

Nuveen LLC bought a new position in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 340,303 shares of the medical equipment provider's stock, valued at approximately $609,000. Nuveen LLC owned approximately 0.33% of Accuray at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ARAY. Ameriprise Financial Inc. acquired a new position in Accuray during the 4th quarter worth about $35,000. ProShare Advisors LLC increased its position in shares of Accuray by 50.7% during the fourth quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider's stock worth $54,000 after acquiring an additional 9,187 shares during the period. MetLife Investment Management LLC increased its position in shares of Accuray by 38.3% during the fourth quarter. MetLife Investment Management LLC now owns 48,234 shares of the medical equipment provider's stock worth $96,000 after acquiring an additional 13,370 shares during the period. Deutsche Bank AG increased its position in shares of Accuray by 44.0% during the first quarter. Deutsche Bank AG now owns 60,606 shares of the medical equipment provider's stock worth $108,000 after acquiring an additional 18,526 shares during the period. Finally, Squarepoint Ops LLC increased its position in shares of Accuray by 36.0% during the fourth quarter. Squarepoint Ops LLC now owns 61,804 shares of the medical equipment provider's stock worth $122,000 after acquiring an additional 16,368 shares during the period. Institutional investors and hedge funds own 64.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ARAY shares. Wall Street Zen lowered Accuray from a "hold" rating to a "sell" rating in a research report on Saturday, August 30th. BTIG Research raised their target price on Accuray from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, Accuray presently has a consensus rating of "Buy" and a consensus target price of $5.00.

Accuray Stock Performance

Shares of ARAY stock remained flat at $1.51 during mid-day trading on Friday. The company's stock had a trading volume of 787,026 shares, compared to its average volume of 800,463. The firm's 50-day moving average price is $1.42 and its two-hundred day moving average price is $1.54. The company has a market capitalization of $170.15 million, a PE ratio of -75.50 and a beta of 1.26. Accuray Incorporated has a 12 month low of $1.14 and a 12 month high of $2.95. The company has a quick ratio of 0.92, a current ratio of 1.65 and a debt-to-equity ratio of 1.53.

Accuray (NASDAQ:ARAY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $127.54 million for the quarter, compared to analysts' expectations of $123.78 million. Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%. Accuray has set its FY 2026 guidance at EPS. On average, research analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.